176 related articles for article (PubMed ID: 32926977)
1. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study.
Yousaf A; Gayam S; Feldman S; Zinn Z; Kolodney M
J Am Acad Dermatol; 2021 Jan; 84(1):70-75. PubMed ID: 32926977
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD
Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207
[TBL] [Abstract][Full Text] [Related]
4. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
5. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
6. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
7. Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate".
Cahn RT; Zinn Z; Kolodney MS
J Am Acad Dermatol; 2023 Jun; 88(6):1385-1386. PubMed ID: 36773822
[No Abstract] [Full Text] [Related]
8. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
Raiker R; DeYoung C; Pakhchanian H; Ahmed S; Kavadichanda C; Gupta L; Kardeş S
Semin Arthritis Rheum; 2021 Oct; 51(5):1057-1066. PubMed ID: 34450504
[TBL] [Abstract][Full Text] [Related]
9. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
[TBL] [Abstract][Full Text] [Related]
10. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study.
Nørgård BM; Nielsen J; Knudsen T; Nielsen RG; Larsen MD; Jølving LR; Kjeldsen J
Br J Clin Pharmacol; 2021 Apr; 87(4):2111-2120. PubMed ID: 33098713
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study.
Kridin K; Schonmann Y; Tzur Bitan D; Damiani G; Peretz A; Weinstein O; Cohen AD
Am J Clin Dermatol; 2021 Sep; 22(5):709-718. PubMed ID: 34060006
[TBL] [Abstract][Full Text] [Related]
13. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
Wu JJ; Guérin A; Sundaram M; Dea K; Cloutier M; Mulani P
J Am Acad Dermatol; 2017 Jan; 76(1):81-90. PubMed ID: 27894789
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
Ho Lee Y; Gyu Song G
Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
[TBL] [Abstract][Full Text] [Related]
16. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease.
Lee WJ; Lee TA; Calip GS; Suda KJ; Briars L; Schumock GT
Inflamm Bowel Dis; 2018 Mar; 24(4):883-891. PubMed ID: 29562275
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
18. Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia.
Jia F; Wang G; Xu J; Long J; Deng F; Jiang W
Aging (Albany NY); 2021 Nov; 13(21):23895-23912. PubMed ID: 34725309
[TBL] [Abstract][Full Text] [Related]
19. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.
Etminan M; Sodhi M; Samii A; Carleton BC; Kezouh A; Antonio Avina-Zubieta J
Semin Arthritis Rheum; 2019 Jun; 48(6):1083-1086. PubMed ID: 30337056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
